Business Context and Reporting Period
Company: Boston Scientific Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2005
Business Overview: A worldwide developer, manufacturer, and marketer of minimally invasive medical devices across interventional cardiology, peripheral interventions, vascular surgery, electrophysiology, neurovascular intervention, oncology, endoscopy, urology, gynecology, and neuromodulation.
Key Financial Metrics
| Metric (in millions) | Q2 2005 | Q2 2004 | YTD 2005 | YTD 2004 |
|---|---|---|---|---|
| Net Sales | $1,617 | $1,460 | $3,232 | $2,542 |
| Gross Profit | $1,260 | $1,097 | $2,531 | $1,887 |
| Gross Margin % | 77.9% | 75.1% | 78.3% | 74.2% |
| Operating Income | $326 | $448 | $839 | $712 |
| Net Income | $205 | $313 | $563 | $507 |
| Diluted EPS | $0.24 | $0.36 | $0.67 | $0.59 |
| Cash from Operations (YTD) | $680 | $574 | ||
| Total Debt (Gross) | $2,056 | $2,367 | ||
| Cash & Equivalents | $698 | $1,296 | ||
| Net Debt | $1,173 | $727 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 11% in Q2 and 27% YTD compared to the prior year. Growth was driven primarily by the TAXUS drug-eluting stent system, which generated $663 million in Q2 sales (up $66 million) and $1.349 billion YTD (up $536 million).
- Profitability Decline: Despite revenue growth, Q2 Net Income dropped 34% to $205 million. This was primarily due to $194 million in purchased research and development (PR&D) charges related to recent acquisitions, $11 million in retirement benefit costs, and increased operating expenses.
- Expense Increases: SG&A expenses rose 26% in Q2 due to sales force expansion and acquisition integration. R&D expenses increased 26% due to internal projects and acquired technologies. PR&D expenses surged from $64 million in Q2 2004 to $203 million in Q2 2005.
- Acquisitions: The company completed four major acquisitions in 2005 (AST, TriVascular, CryoVascular, and Rubicon), resulting in significant intangible asset additions and PR&D charges.
- Debt & Liquidity: Gross debt decreased by $311 million YTD due to the repayment of $500 million in senior notes, partially offset by commercial paper issuances. Cash and cash equivalents declined by $598 million YTD, largely due to $666 million in share repurchases and $174 million in acquisition payments.
Guidance, Outlook, Risks, and Contingencies
- Outlook: Management expects moderate revenue growth for the remainder of 2005. The company anticipates launching the next-generation TAXUS Liberté stent in Europe in H2 2005 and in the U.S. in H2 2006. The Japan launch is expected in 2007.
- Market Dynamics: The company estimates the worldwide coronary stent market will exceed $5 billion in 2005. Conversion from bare-metal to drug-eluting stents is accelerating (88% in the U.S., 45% in Europe/Inter-Continental), though Japan remains a challenge due to competitor launches and pricing pressures.
- Legal Contingencies:
- Johnson & Johnson: Multiple patent infringement suits are ongoing. Juries have found liability for infringement in both directions (Boston Scientific infringing J&J patents and vice versa), but damages have not yet been determined. The company intends to appeal adverse decisions.
- Medinol: Ongoing litigation regarding trade secrets and patent infringement in the U.S. and Europe. A trial in the U.S. began in June 2005.
- DOJ Settlement: The company settled a Department of Justice investigation regarding the 1998 NIR ON Ranger stent recall for $74 million in Q2 2005. No admission of wrongdoing was made.
- Contingent Consideration: The company has potential future earn-out obligations of up to $4.5 billion (undiscounted) tied to regulatory and performance milestones for acquired companies through 2014.
- Accounting Changes: The company will adopt FAS 123(R) regarding stock-based compensation effective January 1, 2006, which will impact future earnings.
Key Facts for Investor Verification
- Acquisition Impact: Verify the integration progress and revenue contribution of the four 2005 acquisitions (AST, TriVascular, CryoVascular, Rubicon) and the associated $276 million in YTD purchased R&D charges.
- TAXUS Stent Performance: Monitor the conversion rates of bare-metal to drug-eluting stents in international markets and the impact of upcoming competitor launches (expected in 2007 in the U.S.).
- Legal Exposure: Track the resolution of damages in the Johnson & Johnson and Medinol patent litigation, as liability has been established but financial impact remains uncertain.
- Capital Allocation: Assess the sustainability of the $666 million share repurchase program alongside continued investment in R&D and acquisitions.
- Japan Market: Verify the timeline for the launch of the TAXUS stent in Japan (expected 2007) given current revenue declines in that region.